Beijing Scitop Bio-tech Co (300858) Fair Value & Analysis
Healthcare · CN · Market cap 4.0B CNY
Fair value as of: Jun 24, 2026
Analysis
Beijing Scitop Bio-tech Co (300858) currently trades at ¥15.40, while our model-based Fair Value estimate is ¥6.23 — implying the stock looks roughly 59.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. The company also offers microecological preparations and related application technologies for ruminants, monogastric livestock and poultry animals, aquatic animals, and pets. In addition, it develops and promotes microbial agents, such as microbial fertilizers, bio-organic fertilizers, organic material decomposition agents, etc. for vegetable, fruit, edible fungus, forage grass, and crop planting. Beijing Scitop Bio-tech Co., Ltd. was founded in 2003 and is headq…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Beijing Scitop Bio-tech Co (300858) undervalued?
What is the fair value of 300858?
What is the quality score of 300858?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.